Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
According to Sudarshan Sukhani of s2analytics.com, one can buy HDFC Bank and feels that one can sell Aurobindo Pharma.
Mitessh Thakkar of miteshthacker.com suggests buying Hexaware Technologies, Elgi Equipments and McDowell Holdings and advises selling Aurobindo Pharma.
Ashish Kyal of Waves Strategy Advisors is of the view that one may buy United Spirits with a target of Rs 2510.
In an interview to CNBC-TV18, Dipan Mehta, Member of BSE & NSE shared his readings and outlook on specific stocks and sector.
Prakash Gaba of prakashgaba.com likes Aurobindo Pharma with target of Rs 725 and Tech Mahindra with target of Rs 500.
Hemant Thukral of Aditya Birla Money is of the view that one can buy Aurobindo Pharma for target of Rs 735 as well as Just Dial.
Prakash Gaba of prakashgaba.com is of the view that Aurobindo Pharma can test Rs 715 while Hindustan Unilever may hit Rs 870.
Prakash Gaba of prakashgaba.com is of the view that Ashok Leyland can climb to Rs 98 while Tata Steel may test Rs 490.
Mitessh Thakkar of miteshthacker.com suggests buying DCB Bank, Larsen & Toubro, Sintex Industries and Aarti Industries and advises selling Aurobindo Pharma.
Sudarshan Sukhani of s2analytics.com is of the view that one can sell Tech Mahindra and Aurobindo Pharma and buy Yes Bank, Tata Chemicals and Havells India.
Mitessh Thakkar of miteshthacker.com suggests buying IndusInd Bank, Bajaj Holdings and Mahindra & Mahindra and advises selling Aurobindo Pharma and Dish TV.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Chambal Fertilisers, Tata Coffee and Aurobindo Pharma.
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today -- Idea Cellular, Sun Pharma, DRL, Lupin, Aurobindo Pharma , Glenmark, Natco Pharma, Alkem Labs, Ajanta Pharma, Strides Shasun, Biocon, Cipla, Cyient, MMTC and Power Grid.
Shahina Mukadam, Independent Market Expert is of the view that one may prefer Larsen and Toubro, State Bank of India and Aurobindo Pharma.
Deutsche Bank expects the market to move in a narrow range during 2017, with recovery likely in the latter part of the year. It says unless the union Budget surprises positively with a tax induced fiscal stimulus, the market is likely to mirror the movement seen in Q416.
Deutsche Bank‘s midcaps top picks are CESC, Petronet LNG, Ramco Cements, REC, Shriram Transport and UPL. Among top large caps, its picks are Aurobindo, BPCL, Maruti, NTPC, SBI, Shree Cement, Tata Motors, TCS, Tech Mahindra, Vedanta India and YES Bank.
Sudip Bandopadhyay, Market Expert is of the view that one can buy MOIL and NMDC even at current level.
Sudarshan Sukhani of s2analytics.com recommends buying Reliance Industries, Marico and Adani Ports.
Nomura has a buy ratings on Dr Reddy‘s, Glenmark, Alkem, Cadila and Jubilant Life. It says Teva‘s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA. Teva expects mid-single digit price erosion in the base US business.
In an interview to CNBC-TV18 Deven Choksey, MD at KRChoksey Investment Managers shared his reading and outlook on the market.
In an interview with CNBC-TV18, SP Tulsian of sptulsian.com gave his stock picks for the day and shared his market outlook.
Ashwani Gujral of ashwanigujral.com recommends buying Century Textiles, Aurobindo Pharma and Petronet LNG.
Ashwani Gujral of ashwanigujral.com is of the view that one may sell Aurobindo Pharma, REC, Vedanta, Bharat Financial Inclusion and HDIL and buy Dabur India and TCS.
Ashwani Gujral of ashwanigujral.com is of the view that one may buy Engineers India and Maruti Suzuki and sell Aurobindo Pharma, Jubilant Foodworks and PFC.
Despite the recent fall in market, SP Tulsian of sptulsian.com maintains his positive stance on back of expectation of a good Budget.